U.S. Markets closed

Trevena says it has 'clear path' to resubmit application for experimental pain medicine

John George
Trevena says it has 'clear path' to resubmit application for experimental pain medicine

The company could not say exactly when it will resubmit is new drug application for oliceridine, which was rejected by the FDA late last year.